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Background and aims: It is as yet unknown whether antithrombin levels are associated with arterial
thromboembolism (ATE) at a young age. To investigate the association between antithrombin levels and
premature and recurrent ATE, we performed a case-control study and a subsequent nested cohort study
of premature coronary heart disease (CHD) patients.
Methods: In the case-control study, we included 571 patients who had a recent premature ATE, including
CHD and ischemic stroke (IS), and 461 healthy controls. The association between antithrombin levels
(dichotomized: median vs. >median) and ATE was investigated. Subsequently we studied the associ-
ation between antithrombin levels and recurrent cardiac events, ATE or death in a nested cohort of 323
CHD patients.
Results: Low antithrombin levels (median, 1.04 IU/mL) are associated with an increased risk of ATE (OR
1.46; 95% CI:1.09e1.96), after adjustment for classical cardiovascular risk factors. This was observed in
the subgroups of CHD patients (1.43; 1.01e2.02) and IS patients (1.48; 1.01e2.19). CHD patients with low
antithrombin levels had a higher risk of recurrent cardiac events (HR 2.16, 95% CI:1.07e4.38). Especially
in women with low antithrombin levels, the risk of recurrent cardiac events was high (HR 5.97, 95% CI
1.31e27.13) as was the risk of recurrent ATE or death (HR 4.22, 95% CI 1.19e15.00).
Conclusions: Individuals with relatively low antithrombin levels have an increased risk for ATE at a
younger age. CHD patients with low antithrombin levels, especially women, have a higher risk of
recurrent cardiac events.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Antithrombin is a strong inhibitor of blood coagulation through
inactivation of mainly thrombin and factor Xa. The anticoagulant
function of antithrombin in vivo is thought to be activated by
heparan sulphate on the vascular endothelium [1]. It has been
suggested that strongly reduced antithrombin levels as in heredi-
tary antithrombin deﬁciency (around 50% of normal) are associated
with arterial thrombotic events (ATE) [2]. Furthermore, a pooled
analysis of four cohort studies showed that inherited thrombo-
philia, including antithrombin deﬁciency, increased the risk of ATE
more pronouncedly inwomen than in men [3]. However, it is as yetroles).
B.V. This is an open access article uunknown whether slightly reduced levels are associated with ATE.
The process of atherosclerosis is driven by traditional cardiovas-
cular risk factors, and the occurrence of ATE is typically caused by
rupture of atherosclerotic lesions and subsequent thrombus for-
mation. A lack of inhibition of thrombus formation, for instance by
low antithrombin levels, may cause acceleration of thrombus for-
mation and increased risk of occlusion of blood vessels. This may
cause an increased risk of ATE [3]. Hemostatic factors are thought to
play a more important pathophysiological role in ATE in young
patients than in older patients because in young individuals
atherosclerosis is not as extensive as in elderly. In addition, in young
patients with myocardial infarction, normal coronary arteries are
more often found than in older patients [4e6]. Indeed, levels of
hemostatic factors such as ﬁbrinogen, TAFI and ADAMTS13 have
been associated with cardiovascular disease at a young age [7e9].
The mortality after myocardial infarction in young patients hasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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interventions [10]. Risk factors for mortality after a myocardial
infarction include heart failure, ventricular arrhythmias, angina
pectoris and re-infarction [11]. Finding more risk factors may allow
for a more precise identiﬁcation of patients at risk for recurrence or
death in those with documented coronary heart disease. We hy-
pothesize that low-normal antithrombin levels are associated with
both a ﬁrst and recurrent ATE at a young age, and may differ be-
tween sexes, as this has been shown before in other thrombophilias
[3]. Therefore, we investigated the association of antithrombin
levels with the risk of ﬁrst and recurrent ATE at a young age,
including a sex-speciﬁc analysis.
2. Patients and methods
2.1. Patients
We performed two related studies: ﬁrst we performed a case-
control study, and subsequently, we performed a follow-up
(cohort-) study of the patients with coronary heart disease from
the ﬁrst study.
2.2. Case-control study
The ‘Genetic risk factors for Arterial Thrombosis at a young age:
the role of TAFI and other Coagulation factors (ATTAC)’ study is a
single-center, case-control study investigating the role of coagula-
tion factors on incidence of ATE at a young age. The design of the
study and recruitment of patients and controls have been reported
elsewhere in detail [7,8]. In short, cases were consecutive patients
who presented with a ﬁrst acute arterial ischemic event in our
center. Our center is a university hospital with a community
function, located in the city centre. Our center employs no selection
criteria of admission of cardiovascular patients, but young patients
are over-represented. Patients were men aged 45 years or younger
or women aged 55 or younger. The case-control study originally
consisted of three subgroups: Group CHD: coronary heart disease,
including acute myocardial infarction and unstable angina pectoris
(CHD); group IS: ischemic stroke (IS) or transient ischemic attack
(TIA); and group PAD: peripheral arterial disease (PAD). Patients
were included 1e3months after the event, to avoid a possible acute
phase response on plasma levels of the parameters investigated.
Controls were neighbours or friends of the patients. They fulﬁlled
the same age criteria but did not have a history of ATE.
2.3. Follow-up study
The 368 subjects included in the ATTAC study who presented
with coronary heart disease were asked to participate in a follow-
up study as reported elsewhere in more detail [9]. These subjects
were followed at the outpatient clinic (and by telephone in case this
was not possible) for recurrent cardiac events and for any recurrent
cardiovascular event or all-cause mortality.
Participants were included in the study after written informed
consent, between October 2001 and June 2010. Both the ATTAC and
the follow-up studies were approved by the institutional Medical
Ethics Committee of the Erasmus MC, and both conform to the
ethical guidelines of the 1975 declaration of Helsinki.
2.4. Deﬁnitions
The deﬁnitions used in this study have been reported elsewhere
[8]. In short, CHD was deﬁned as acute myocardial infarction (AMI)
or unstable angina pectoris (UAP). AMI was deﬁned as typical chest
pain, with elevated cardiac markers (CK MB/troponin T), and/orcharacteristic electrocardiographic ﬁndings. UAP was deﬁned as
typical chest pain at rest. Transient ischemic attack (TIA) was
deﬁned as the acute onset of focal cerebral dysfunction, which
could not be explained otherwise than by focal cerebral ischemia,
as diagnosed by a neurologist. Symptoms had to be temporary and
last less than 24 h. Ischemic stroke (IS) was deﬁned as the acute
onset of focal cerebral dysfunction as a result of cerebral ischemia,
with symptoms lasting longer than 24 h. Brain imaging by CT-scan
and MRI-scan had to be compatible with the diagnosis and were
used to rule out intracerebral hemorrhage. Smoking status was
deﬁned as self-reported never, previous or current smoker. Hy-
percholesterolemia was originally deﬁned as a subject-reported
presence of hypercholesterolemia or the use of lipid lowering
treatment on the day of the event. As most cases used cholesterol
lowering medications at inclusion, cholesterol measurements were
not representative of cholesterol levels before the event. Therefore,
in the case-control study, cholesterol was not adjusted for in the
analyses. In the follow-up study, as nearly all patients used lipid-
lowering treatment, cholesterol levels were adjusted for in the
analyses. Patients with a medical history of diabetes or using either
oral anti-diabetic medication or insulin therapy on the day of the
event were considered to have diabetes. Hypertension was deﬁned
by a systolic blood pressure 140mmHg, and/or diastolic blood
pressure 90mmHg or the use of anti-hypertensive drugs.
In the follow-up study we used the endpoints recurrent cardiac
event (deﬁned as myocardial infarction or revascularization pro-
cedure) and any recurrent arterial thrombotic event or death
(deﬁned recurrent cardiac event, cerebrovascular event (IS or TIA)
or all-cause mortality). At the time of inclusion in the study, direct
acting oral anticoagulants were not yet registered in the
Netherlands.2.5. Blood sampling
Blood was collected 1e3 months after the event in sodium cit-
rate (ﬁnal concentration 0.105M) using a Vacutainer System
(Beckton, Dickinson and Company, Plymouth, UK) and centrifuged
at 2000g for 10min at 4 C. Plasma was additionally centrifuged for
10min at 20,000g for 10min at 4 C and stored in aliquots
at80 C. Technicians were not aware of the caseecontrol status of
the samples. Antithrombin activity measurements were performed
using the factor Xa-based INNOVANCE® Antithrombin assay kit
(Siemens). Measurements of samples were performed once, but AT
values outside the reference range were performed in duplicate.
Cholesterol and HDL were determined on Modular Analytics®
(Roche Diagnostics, Mannheim, Germany).2.6. Statistical analysis
Descriptive statistics were used in both studies. The data are
presented as means± standard deviation.2.6.1. Case-control study
To compare levels of the normally distributed risk factors be-
tween groups, ANOVA's were performed with adjustment for age
and sex. We performed logistic regression for ATE with anti-
thrombin activity as a continuous variable and as a binominal
variable, using the predeﬁned cut-off-levels of the lower limit of
the reference range (0.80 U/mL) and the median antithrombin
level of controls. Logistic regression analyses were adjusted for age,
sex, BMI, smoking, family history, hypertension, diabetes mellitus.
In addition, separate sex-speciﬁc analyses were performed,
adjusted for the same cardiovascular risk factors.
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In the follow-up study, cumulative event-free survival curves
were constructed using the Kaplan-Meier method. Comparisons in
the Kaplan-Meier curves were performed using the Log-rank test.
The median antithrombin level of the cohort of CHD patients was
the predeﬁned cut-off level. To determine by how much low anti-
thrombin levels in this cohort increase the risk of ATE, Cox-
regression analysis was performed with the median antithrombin
levels after adjustment for age, BMI and sex, and after adjustment
for age, BMI and sex, family history, cholesterol, HDL, hypertension,
diabetes, and smoking (at inclusion).
All statistical analyses were performed using SPSS for Windows,
version 21 (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Case-control study
The ATTAC study included a total of 1157 participants. For 76
participants (38 cases, 38 controls), plasmawas no longer available,
and 49 were PAD patients. This current study, therefore, included
1032 individuals, of whom 571 CHD and IS cases and 461 healthy
controls. Forty-ﬁve percent of cases (257/620) and thirty-ﬁve
percent of controls (162/461) were men. The mean age was 39.8,
standard deviation (SD) ±7.8 for cases and 43.0 SD± 6.8 for con-
trols. As expected, traditional risk factors were more prevalent in
cases than in controls (Table 1).
When investigating classical risk factors for ATE using logistic
regression, we found that age (OR 1.05, 95% CI:1.03e1.07), male sex
(OR 2.08, 95% CI: 1.54e2.83), family history of cardiovascular dis-
ease (OR 2.25, 95% CI:1.66e3.05), hypertension (OR 3.98, 95%
CI:2.54e6.24), and diabetes (OR 4.90, 95% CI: 2.17e10.89) were
signiﬁcantly associated with ATE. Hypercholesterolemia was asso-
ciated with a lower risk of ATE (OR 0.65, 95% CI:0.43e0.96).
The median of antithrombin activity was similar across controlsTable 1
Patient characteristics of the ATTAC case-control study on the risk of a ﬁrst arterial throm
Controls (n¼
Demographics
Age, mean (years) 39.8± 7.8
Men, n (%) 162 (35.1)
Body mass index, mean (kg/m2 ±SD) 25.7± 4.5
Index event
UAP þ AMI (n)
Stroke þ TIA (n)
Risk factors
Family history of ATE (%) 22.6
Smoking (former þ current) (%) 52.5
Hypertension (%) 6.5
Systolic blood pressure, mmHg, median ±SD 123 ± 16
Diastolic blood pressure, mmHg, median ±SD 80 ± 11
Diabetes (%) 1.7
Cholesterol, mean, ±SD 5.17± 0.94
LDL, mean, ±SD 3.17± 0.89
HDL, mean, ±SD 1.52± 0.43
Antithrombin activity (U/mL, SD) 1.04± 0.10
Antithrombin activity 0.80 U/mL 4
Medication at study entry
Platelet function inhibitor 5
Vitamin K antagonist 4
Вeta-blocker 14
Ace-inhibitor or A2 antagonist 12
Calcium blocker 1
Diuretic 7
Statin or ﬁbrate 9
n: number. UAP: unstable angina pectoris. AMI: acute myocardial infarction. TIA: transien
density lipids. HDL: High density lipids.and subtypes of cases (in controls, CHD and IS: 1.04 U/mL). The
distribution of antithrombin levels in the three groups is shown in
Fig. 1. Since the distribution approached a normal distribution
(even though the Kolmogorov-Smirnov test did not support a
normal distribution), we performed parametric statistics, since this
enables us to adjust for confounders and effect modiﬁers. Ten
participants had antithrombin values 0.80 U/mL (lower limit of
reference range). Logistic regression without adjustment for clas-
sical risk factors showed no predictive value of antithrombin ac-
tivity as a continuous variable (OR1.53; 95% CI:0.48e4.89) or at the
cut-offs of 0.80 U/ml (OR 1.21; 95% CI:0.34e4.33) and median
antithrombin level (1,04 U/ml) (OR 1.12; 95% CI:0.87e1.43).
However, when using antithrombin activity as a binary variable
with predeﬁned cut-off of the median antithrombin level, a 46%
increased risk of ATE was found in the adjusted analysis for the
participants with low antithrombin levels (OR 1.46; 95%
CI:1.09e1.96). Similar results were found in the CHD group (OR
1.43; 95% CI:1.01e2.02) and in the IS group (OR 1.48; 95% CI:
1.01e2.19). In a separate sex-speciﬁc analysis, no major differences
were found between men and women. To investigate if the higher
age at inclusion for women inﬂuenced results, womenwith the age
of 46 or older were excluded. The adjusted OR was 1.55, 95% CI:
1.09e2.21. These results are summarized in Table 2.3.2. Follow-up study
Three-hundred-ﬁfty-three subjects with coronary heart disease
entered the ATTAC follow-up study, of whom only 323 subjects
could be evaluated, because no blood samples were available from
30 patients. Those subjects consisted of 181 men and 142 women,
characteristics are summarized in Supplemental Table 1. At study
entry, the median age was 42 years for men and 47 years for
women. Seventy-one percent had single vessel disease. Most pa-
tients (94%) received a stent: 9% a bare metal stent, 85% a drug-
eluting stent. No coronary artery bypass surgery was performed.boembolism.
461) Cases (n¼ 571) p-value
43.0± 6.8 <0.01
257 (45.0) <0.01
27.0± 4.7 <0.01
368
203
51.5
75.7 <0.01
28.2 0.12
122± 21
80± 13
10.2 <0.01
4.29± 0.96 <0.01
2.51± 0.85 <0.01
1.29± 0.42 <0.01
1.04± 0.11 0.77
6 0.47
541
47
229
293
48
72
483
t ischaemic attack. ATE: arterial thromboembolism. SD: standard deviation. LDL: low
Fig. 1. Distribution of antithrombin levels across categories in the ATTAC study.
Distributions of antithrombin levels in all subjects (A), controls (B), coronary heart disease (CHD) patients (C) and in ischaemic stroke (IS) patients (D).
Table 2
Antithrombin as risk factor for a ﬁrst arterial thromboembolism in the ATTAC case-control study.
CHD þ IS CHD IS
Antithrombin continuous
Unadjusted 1.53; 0.48e4.89
Adjusteda 0.46; 0.12e1.85 0.44; 0.09e2.28 0.58; 0.09e3.68
Antithrombin median or lower (1.04 U/mL)
Unadjusted 1.12; 0.87e1.43
Adjusteda 1.46; 1.09e1.96 1.43; 1.01e2.02 1.48; 1.01e2.19
Men, adjusteda 1.38; 0.86e2.24 1.27; 0.76e2.13 1.97; 0.92e4.20
Women, adjusteda 1.46; 1.00e2.14 1.56; 0.97e2.52 1.33; 0.84e2.12
Subjects aged <46, adjusteda 1.55; 1.09e2.21
Antithrombin deﬁciency (0.80 U/mL)
Unadjusted 1.21; 0.34e4.33
Adjusteda 1.52; 0.33e7.01 1.42; 0.19e10.54 2.06; 0.36e11.84
CHD: coronary heart disease. IS: ischemic stroke. Bold: statistically signiﬁcant effect.
a Adjusted for all cardiovascular risk factors.
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pressure lowering drugs and 95% used statins. Median follow-uptime was 3.6 years (range 0.05e9.36 years). Nine patients (3%)
died and 37 (11%) had a recurrent arterial thrombotic event.
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had a recurrent event or death. In the total group age, sex and BMI
did not differ between patients with or without a recurrent event.
Of the 142 women, 45 were postmenopausal, 97 were not. In
postmenopausal women antithrombin levels were higher than in
premenopausal women mean in premenopausal women 1.01U/ml
±0.10, in postmenopausal women 1.07± 0.11 (p¼ 0.008).
Classical cardiovascular risk factors were not associated with
recurrent events. A sex-speciﬁc analysis showed that diabetes was
associated with recurrent events or death in men (HR 3.74, 95% CI
1.15e12.12). In women, none of the classical cardiovascular risk
factors were associated with recurrence. Furthermore, menopausal
state or use of oral contraceptives was not associated with recur-
rence. For a summary, see Table 3.
The median antithrombin level was 1.04 ± 0.11 U/ml in the total
CHD cohort, 1.05± 0.11 U/ml in men and 1.02± 0.11 U/ml inwomen
(men vs. women, p¼ 0.003).
In the total group of CHD patients, Kaplan-Meier analysis
showed that patients with lower antithrombin levels, predeﬁned
asmedian level of the cohort (1.04 U/mL), had a signiﬁcantly
higher risk of recurrent cardiac events (p¼ 0.03). When stratiﬁed
by sex, this was observed only inwomen (p¼ 0.021) but not in men
(p¼ 0.88) (Fig. 2). Regarding recurrent ATE and death, a higher risk
of events was found for participants with lower antithrombin levels
(predeﬁned asmedian), but this was not signiﬁcant (p¼ 0.12).
When stratiﬁed by sex, womenwith lower antithrombin levels had
a signiﬁcantly higher risk of events (p¼ 0.012) than women with
higher antithrombin levels, while no difference was seen in
recurrent ATE or death between higher or lower antithrombin in
men (p¼ 0.82).
In the total group of CHD patients, patients with lower
(median) antithrombin levels had a higher chance of a recurrent
cardiac event, with a HR of 2.11, 95% CI 1.06e4.21; after adjustment
for age, BMI and sex: HR 2.12 95% CI 1.06e4.26; and adjustment for
all risk factors: HR 2.16, 95% CI:1.07e4.38. Women with lower
antithrombin levels had a higher rate of recurrent cardiac events:
HR 6.01, 95% CI 1.38e26.24; after adjusting for age and BMI: HR
6.08, 95% CI 1.38e26.84; after adjusting for all risk factors: HR 5.97,
95% CI 1.31e27.13. In men, after adjusting for all risk factors no
signiﬁcant difference was found, HR 1.18, 95% CI 0.46e3.03.
For recurrent ATE and death in all CHD patients, no signiﬁcantly
different event free survival was observed for participants with
lower antithrombin (adjusted for all factors: HR 1.67, 95% CI
0.92e3.02). After stratifying by sex, only women with lower anti-
thrombin levels had a higher risk of recurrent ATE or death, with a
HR of 4.2 (95% CI 1.25e14.69); after adjustment for age and BMI: HR
4.38 (95% CI 1.26e15.17); after adjustment for all cardiovascularTable 3
The risk of recurrent arterial events or death in the follow-up study.
Traditional cardiovascular risk factors, median antithrombin and sex. Cox regression an
median antithrombin levels and the risk of recurrent arterial thrombotic events or death
Any recurrent event
HR (95% CI)
Age 0.97 (0.92e1.03)
Female sex 1.05 (0.51e2.17)
Family history of cardiovascular disease 1.04 (0.58e1.88)
Hypertension 0.78 (0.36e1.67)
Diabetes 1.02 (0.35e2.96)
Smoking, current 0.92 (0.41e2.09)
Smoking, former 0.62 (0.24e1.58)
Total cholesterol 1.25 (0.88e1.78)
HDL 1.10 (0.45e2.67)
BMI 0.97 (0.90e1.03)
Median antithrombin (1.04 U/mL) 1.67 (0.92e3.02)
HR: hazard ratio. HDL: high density lipids. BMI: body mass index.factors: HR 4.22 (95% CI 1.19e15.00).
4. Discussion
The main ﬁnding of the case-control study is that reduced
antithrombin levels (median) are associated with an increased
risk for arterial thrombosis at a young age (OR 1.46; 95%
CI:1.09e1.96) when compared with individuals with high-normal
(>median) antithrombin levels, after adjusting for major cardio-
vascular risk factors. This effect is most pronounced in women. In
addition, lowantithrombin levels are also associatedwith recurrent
events in young individuals with CHD (HR 2.16, 95% CI:1.07e4.38).
Antithrombin deﬁciency is the ﬁrst reported cause of inherited
thrombophilia [12], and it is a rare but strong risk factor for venous
thromboembolism (VTE). The risk of ﬁrst VTE is increased up to 16
folds [13]. Furthermore, an inverse relationship between the risk of
VTE and antithrombin levels within the normal range has been
described; as compared with individuals with high-normal anti-
thrombin levels, in individuals with antithrombin levels in the
lower-normal range, the risk of VTE is signiﬁcantly increased [14].
Although venous and arterial thromboembolism are believed to be
different disease entities, risk factors overlap. Inherited thrombo-
philia is not only associated with VTE, but also with an 1.7-fold
increased risk of arterial thromboembolism (ATE), as shown in a
combined analysis of four studies on thrombophilic families [3].
The ﬁnding thatmedian antithrombin levels are associated
with an increased risk for arterial thrombosis at a young age is in
part in line with previous studies. These studies focused on
inherited antithrombin deﬁciency and thus on much lower anti-
thrombin levels (usually 0.80 U/ml). In a large prospective study
in families with thrombophilia, an up to 9-fold increased risk of ATE
in individuals with inherited thrombophilia was observed [2]. In
this study, antithrombin deﬁcient individuals had a 7-fold
increased risk of ATE. More recently, a pooled analysis of four
family studies by Mahmoodi et al. showed that inherited throm-
bophilia overall is a risk factor for ATE [3]. This risk was even more
pronounced in individuals below the age of 55 and in women.
However, antithrombin deﬁciency by itself failed to show an as-
sociation (HR 1.36, 95% CI 0.55e3.34), possibly due to a lack of
power, since only 72 antithrombin deﬁcient participants were
included in this analysis. Antithrombin levels were not associated
with the incidence of ischemic stroke and coronary heart disease in
the ARIC study, a large, prospective population study. Of note, the
individuals included in this study were older (age at inclusion
45e64) than in our study population, which included males aged
45 and females aged 55 years [15,16]. In the prospective
Northwick Park Heart Study, antithrombin levels and thealysis to assess the relationship between traditional cardiovascular risk factors and
(all-cause). None of the 19 women with diabetes had an event.
Men
HR (95% CI)
Women
HR (95% CI)
0.95 (0.87e1.03) 1.01 (0.94e1.10)
0.79 (0.35e1.80) 1.33 (0.53e3.36)
0.83 (0.26e2.67) 0.96 (0.33e2.83)
3.74 (1.15e12.12)
0.78 (0.23e2.58) 0.36 (0.05e2.46)
0.52 (0.17e1.56) 1.83 (0.46e7.29)
1.30 (0.82e2.04) 0.85 (0.43e1.68)
0.84 (0.23e3.06) 2.58 (0.69e9.66)
0.93 (0.84e1.03) 1.01 (0.92e1.12)
1.06 (0.48e2.35) 4.22 (1.19e22.56)
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only, aged 40e64. In this study, individuals with antithrombin
levels in the lowest tertile had a higher risk of death from arterial
disease when compared to the middle tertile [17]. However, this
was also observed for the highest tertile as compared to the middle
tertile. The increased risk of ATE associated with low antithrombin
levels, in our large patient population with a ﬁrst manifestation of
ATE at an even younger age, is therefore a novel and interesting
ﬁnding.
In order to investigate whether antithrombin levels are associ-
ated with the risk of recurrent ATE, we subsequently followed 323
patients with CHD from our case-control study, during a median of
3.6 years, for recurrent events. The main ﬁnding is that lower
antithrombin levels were associated with a higher risk of recur-
rence, with a HR of 2.16, 95% CI:1.07e4.38. Themain contribution to
the increased risk comes from women with lower (median)
antithrombin levels. Women with lower antithrombin levels did
not only have a high rate of recurrent cardiac events (HR 5.97, 95%
CI 1.31e27.13), but also of recurrent ATE and death (HR 4.22, 95% CI
1.19e15.00) as compared to women with higher antithrombin
levels. Formen, having amedian antithrombin level was not a risk
factor. This sex-speciﬁcity of lower antithrombin levels on recur-
rence risk of CHD has not been reported before, but gender speci-
ﬁcity for thrombophilia as a risk factor for a ﬁrst ATE has been
reported before [3]. In IS patients, familial thrombophilia has been
reported as risk factor for recurrent ATE, but antithrombin levels
were not investigated [18]. Only one study has previously investi-
gated the role of antithrombin levels on recurrent ATE in CHD pa-
tients. In a prospective cohort study by Pelkonen et al. on acute
coronary syndrome patients, patients who had a recurrent arterial
event had lower antithrombin levels than patients who had no
recurrence [19]. However, these subjects were mostly male, and
substantially older (64± 10 years) than in our study (43.6± 5.8
years). No sex-speciﬁc analysis was performed in this study, and
therefore it is difﬁcult to compare the results. The pathogenetic
explanation of how lower antithrombin levels increase recurrence
risk only in women has not yet been resolved. Many other gender
differences in (risk factors of) coronary heart disease have been
reported before [20].
Current concepts of the pathways involved in thrombus for-
mation in acute coronary syndrome include both platelet activation
and ﬁbrin formation [21]. The latter pathway is controlled by
antithrombin [1]. The hypothesis that lower antithrombin levels
would increase the risk of (recurrent) cardiac events by tilting the
hemostatic balance towards a more prothrombotic phenotype
seems logical. When patients present with ATE, many of the risk
factors causing the ﬁrst arterial event such as hypercholesterole-
mia, diabetes, hypertension and possibly factors related to primary
hemostasis will be actively managed by lifestyle adjustments or
medication, as in our cohort. Therefore, other possible risk factors
pertaining to inhibition of thrombin formation may become more
apparent. Through these risk factors high-risk patients may be
identiﬁed and potentially treated differently.
Our studies have limitations. The chosen deﬁnition of hyper-
cholesterolemia at inclusion in the study, which includes the use of
statins, irrespective of the reasonwhy theywere prescribed, did not
allow for an adequate analysis of this in the case-control study. The
different age-limit for men and women for inclusion in the study
could have an effect on results, however, when excluding subjectsFig. 2. Recurrent cardiac event-free survival according to median antithrombin levels.
(A) Recurrent cardiac event-free survival overall. (B) Recurrent cardiac event-free
survival in women. (C) Recurrent cardiac event-free survival in men. Black bars:
antithrombin level>median (1.04 U/mL); grey bars: antithrombin levelmedian
(1.04 U/mL).
F.Nanne. Croles et al. / Atherosclerosis 269 (2018) 144e150150(women) of age 46 or older, the effect of low antithrombin levels in
the case-control-study was more pronounced, HR 1.55; 95% CI
1.09e2.21. The blood samples may have been inﬂuenced by post-
event changes such as coagulation activation [22,23]. This was,
however, not tested. Therefore, the association of low antithrombin
levels and ATE can result from the ATE itself through coagulation
activation, or a lowantithrombin levels may be a contributing cause
of ATE. Post-event inﬂammation is unlikely to have played a role as
hsCRP levels were low. At inclusion in the study and drawing of
blood, 95% of patients used platelet function inhibitors and 8%
vitamin K antagonists. Previous studies have shown that vitamin K
antagonists (warfarin) do not change antithrombin levels [24]. We
are unaware of studies showing that platelet inhibiting drugs
(clopidogrel, aspirin) inﬂuence antithrombin levels. None of the
subjects used (low-molecular-weight-) heparin at the time of blood
sampling.
Although our follow-up study of young patients with a ﬁrst
cardiac event is quite large for these type of patients, the number of
recurrent events was still low. This limits the statistical power to
detect risk factors. Therefore, a rather crude cut-off of median
antithrombin levels was chosen to investigate if there was any ef-
fect. If on a population level a more narrow cut-off is more pre-
dictive is unknown. This limits the use of antithrombin levels as a
predictive tool in practice based on this study alone. The low sta-
tistical power may also explain that, of the classical cardiovascular
risk factors, only diabetes in men was a signiﬁcant risk factor for
recurrence, while other classical cardiovascular risk factors were
not. Even so, risk factors for ﬁrst and recurrent events are not
necessarily the same [25]. Despite this, the ﬁnding of a high risk in
women with low antithrombin levels for ATE and recurrent ATE
seems to be robust and in line with previous studies [3], but should
be validated in further studies. Another limitation of the follow-up
study is the lack of information on adherence to medications pre-
scribed, as non-adherence has been shown to be an important risk
factor for recurrent ATE [26].
In conclusion, we found that lower antithrombin levels increase
the risk of a ﬁrst arterial thrombotic event at a young age. Lower
antithrombin levels are associated with a higher rate of recurrent
cardiac events and with a higher rate of recurrent arterial throm-
boembolism or death in women.Conﬂicts of interest
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